Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mike M who wrote (2253)	2/11/2000 9:20:00 AM
From: Hank	Respond to of 5582

"..you are going to great lengths to condemn them with knowing them." Not true. I only make mention of management because you brought it up. They have never been the focus of my criticisms. What I condemn is the blatant lack of valid, verifiable, data regarding their claims for Zicam. As for management's prowess as business people, I'd have to say they are pretty good. After all, they've done a bang up job at manipulating the media, large investors, and public opinion in the absence of any real proof that Zicam even works. If I ever come up with a quick buck fad product I'd like to market, I'd hire these guys in a second.

To: Mike M who wrote (2253)	2/11/2000 9:36:00 AM
From: out_of_the_loop	Respond to of 5582

Gum Tech Redeems Obligation to Citadel Investment Group biz.yahoo.com Friday February 11, 9:01 am Eastern Time Company Press Release SOURCE: Gum Tech Gum Tech Redeems Obligation to Citadel Investment Group PHOENIX, Feb. 11 /PRNewswire/ -- Gum Tech (Nasdaq: GUMM - news) announced today that it has redeemed its entire obligation to Citadel Investment Group. Gum Tech secured a financing arrangement with Citadel on June 2, 1999, for $6 million in combined debt and preferred equity. The company used the proceeds primarily to capitalize its Gel Tech LLC joint venture and continue its development work on nicotine gum. William Hemelt, Gum Tech's Chief Financial Officer, said, ''We satisfied our obligation to Citadel with a final issuance of stock within the last two weeks. We are pleased that we were able to satisfy our obligation in such a short period of time, with very little dilution to shareholders. In effect, we issued stock at substantially higher prices than we could have under a more traditional stock offering last year, which resulted in the issuance of substantially fewer shares. We will retain our cash resources for current and future projects.'' ''The Citadel financing was critical in enabling us to pursue a number of important projects, including the successful launch of Zicam(TM) and the pending joint venture with Swedish Match,'' continued Mr. Hemelt. ''Both those projects are taking us into two very large markets, the cough and cold remedy category and the non-tobacco nicotine category. We successfully leveraged the Citadel financing into actual sales and profitability. By redeeming our obligation to Citadel now, and repaying the remainder of the company's debt within the near future, we will essentially eliminate the burden of our interest and dividend expense.'' Hemelt concluded by noting that Gel Tech LLC, the joint venture between Gum Tech and BioDelivery Technologies to develop, market and distribute Zicam(TM), recently secured a $1 million dollar revolving line of credit with Imperial Bank. Gum Tech is located at 246 East Watkins Street, Phoenix, Arizona 85004. (Nasdaq: GUMM - news) E-mail: brown@gum-tech.com Gum Tech's Forward-Looking Statement: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's anticipated growth in business and future results of operations, continued growth in sales in Zicam(TM), and implementation of its nicotine and dental gum strategies. These forward-looking statements are based on the company's expectations and are subject to a number of risks and uncertainties, many of which cannot be predicted or quantified and are beyond the company's control, including the possibility that the company may require additional financing in the future, fail to maintain the initial success of Zicam(TM), or fail to develop a successful product through its joint venture with Swedish Match. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from the company's expectations are described in the company's reports filed pursuant to the Securities Exchange Act of 1934. SOURCE: Gum Tech